This technology is method for treating myelodysplastic syndrome (MDS) with a broad specificity kinase inhibitor, rigosertib, that can be used in combination with other therapies.
Unmet Need: Effective treatment for MDS and other refractory cancers
While investigational drug therapies exist, there is currently not a curative drug treatment for most hematological cancers. Current treatment strategies for hematopoietic cancers include: allogeneic stem cell transplantation, chemotherapy, erythropoietin-stimulating agents, blood transfusion, and DNA methyltransferase inhibitors. However, none of these treatment strategies are curative and since hematopoietic cancers are biologically complex heterogeneous diseases, a single treatment strategy may not work for all patients. Thus, there is an urgent need for developing treatments for patients with hematopoietic and/or hematological cancer whose disease no longer responds to existing drugs.
The Technology: Effective treatment for hematologic cancers that can be used in combination with other therapies
This technology provides a method for treating MDS with rigosertib. The multi‐kinase inhibitor rigosertib induces mitotic arrest and apoptosis in myeloblasts, while sparing normal cells. This therapeutic can be delivered intravenously or orally, which has been demonstrated to be bioavailable and well tolerated in patients. As a result, this technology offers an effective therapeutic strategy for treating MDS that can be used in combination with chemotherapy or radiotherapy to treat or ameliorate symptoms and prolong patient survival.
This technology has been validated in Phase I clinical trials.
Applications:
- Oral medication for the acute treatment of in low-risk MDS patients
- Oral medication for the treatment of refractory solid tumors such as ovarian, prostate, breast, etc.
- Combination therapy with chemotherapeutic agents
- Drug for patients with complications with IV administration
Advantages:
- Easy self-administration
- Low risk of complications
- Cost effective
- Rapid response with desirable safety profile
- Can serve as a single medication or a combinational drug
Lead Inventor:
Azra Raza, M.D.
Patent Information:
Patent Pending (US 20150313859)
Related Publications:
Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. “Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes” British Journal of Haematology 2013 Jun; 162(4): 517-524.
Raza A, Tycko B, Lee S, Galili N, Ali A, Eisenberger A, Mears JG, Al-Kali A, Tibes R, Spitzer G, Wilhelm F, Mukherjee S. “Oral rigosertib (ON 01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients; a genomic methylation profile is associated with responses” Blood 2013; 122: 2745.
Raza A, Mukherjee S, Eisenberger A, Mears G, Wilhelm F. “Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients” Journal of Clinical Oncology 2013 May; 31(15): 7031
Komrokji RS, List AF, Wilhelm F, Lancet JE, Raza A. “Oral formulation of rigosertib (ON 01910.Na) in patients with myelodysplastic syndrome (MDS) – phase I study results” Blood 2011; 118: 3797.
Tech Ventures Reference: